OBIO (Orchestra BioMed Holdings) Margin of Safety % (DCF Dividends Based): N/A (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OBIO Orchestra BioMed Holdings Inc OBIO
42 GF Score
Price $5.81
GF Value $31.58
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Orchestra BioMed Holdings Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Orchestra BioMed Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

OBIO vs CYDY, IRD, VNDA: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Orchestra BioMed Holdings's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchestra BioMed Holdings Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Margin of Safety % (DCF Dividends Based) falls into.


OBIO
42GF Score
Orchestra BioMed Holdings Inc OBIO
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orchestra BioMed Holdings (OBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Orchestra BioMed Holdings stock appears to be undervalued. The current stock price of $5.81 is trading 81.6% below its estimated GF Value™ of $31.58. GuruFocus considers Orchestra BioMed Holdings to be Possible Value Trap.

Key valuation signals for OBIO:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $31.58 vs. price of $5.81 (81.6% below fair value)
  • GF Score™: 42/100 with 6 warning signs

No single metric tells the full story. See the OBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orchestra BioMed Holdings Business Description

Address 150 Union Square Drive, New Hope, PA, USA, 18938
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
42GF Score

Get the complete analysis for OBIO

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.81
Price
$31.58
GF Value